Literatur
Anscher MS, Prosnitz LR (1989) Radiotherapy vs. hormonal therapy for the management of locally recurrent prostate cancer following radical prostatectomy. Int J Radiat Oncol Biol Phys 17: 953–958
Anscher MS, Robertson CN, Prosnitz LR (1995) Adjuvant radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate: ten year update. Int J Radiat Oncol Biol Phys 33: 37–43
Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Gil T, Colette L, Pierart M (1997) Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337: 295–300
Borghede G, Hedelin H, Holmäng S, Johansson KA, Aldenborg F, Pettersson S, Sernbo G, Wallgren A, Mercke C (1997) Combined treatment with temporary short-term high dose rate Iridium-192 brachytherapy and external beam radiotherapy for irradiation of localized prostatic carcinoma. Radiother Oncol 44: 237–245
Catalona WJ, Smith DS (1995) 5-year tumour recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 152: 1837–1843
Cheng WS, Frydenberg M, Bergstrahl EJ, Larson-Keller JJ, Zinke H (1993) Radical prostatectomy for pathologic stage C prostate cancer: influence of pathologic variables and adjuvant treatment on disease outcome. Urology 42: 283–291
D’Amico AV, Whittington R, Kaplan I, Beard C, Jiroutek M, Malkowicz SB, Wein A, Coleman CN (1997) Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment proostate specific antigen of > 4–20 ng/ml. Int J Radiat Oncol Biol Phys 37: 1053–1058
Dinges S, Deger S, Koswig S, Boehmer D, Schnorr D, Wiegel T, Loening SA, Dietel M, Hinkelbein W, Budach V (1998) High-dose rate interstitiell with external beam irradiation for localized prostate cancer-results of a prospective trial. Radiother Oncol (in press)
Fuks Z, Leibel SA, Wallner KE, Begg C, Fair WR, Anderson LL, Hilaris BS, Whitmore WF (1991) The effect of local control on metastatic dissemination in carcinoma of the prostate. Long-term results in patients treated with 125J implantation. Int J Radiat Oncol Biol Phys 21: 537–547
Huddart RA, Rajan B, Law M, Meyer L, Dearnaley (1997) Spinal cord compression in prostate cancer: treatment outcome and prognostic factors. Radiother Oncol 44: 229–237
Kaplan ID, Bagshaw MA (1992) Serum prostate-specific antigen after post-prostatectomy radiotherapy. Urology 39: 401–406
Kupellian P, Katcher J, Levin HS, Klein EA (1997) Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. Int J Radiat Oncol Biol Phys 37: 1043–1052
Lange PH, Lightner DJ, Medini E, Reddy PK, Vesella RL (1990) The effect of radiation therapy after radical prostatectomy in patients with elevated prostate specific antigen levels. J Urol 144: 927–932
Link P, Freina FS, Stamey TA (1991) Adjuvant radiation therapy in patients with detectable prostate specific antigen following radical prostatectomy. J Urol 145: 532–534
Lightner DJ, Lange PH, Reddy PK, Moore L (1990) Prostate specific antigen and local recurrence after radical prostatectomy. J Urol 144: 921–926
Morgan WR, Bergstrahl EJ, Zincke H (1993) Long-term evaluation of radical prostatectomy as treatment for clinical stage C (T3) prostate cancer. Urology 41: 116–120
Ohori M, Wheeler TM, Kattan MW, Goto Y, Scardino PT (1995) Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 154: 1818–1824
Partin AW, Pound CR, Clemens JQ, Epstein JI, Walsh PC (1993) Serum PSA after anatomic radical prostatectomy: the John Hopkins experience after 10 years. Urol Clin North Am 20: 713–725
Partin AW, Pearson JD, Landis PK, Carter HB, Pound CR, Clemens JQ, Epstein JI, Walsh PC (1994) Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 43: 649–659
Paulson DF et al (1982) Radical surgery versus radiotherapy of adenocarcinoma of the prostate. J Urol 128: 502–504
Perez CA, Eisbruch A (1993) Role of postradical prostatectomy irradiation in carcinoma of the prostate. Semin Radiooncol 3: 198–209
Pilepich MV, Krall JM, al Sarraf M, John M, Doggett MJ, Sause WT, Lawton CA, Abrams RA, Rotman M, Rubin P (1995) Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 45: 616–623
Schild SE, Buskirk SJ, Robinow JS, Tomera KM, Ferrigni RG, Frick LM (1992) The results of radiotherapy for isolated elevation of serum PSA levels following radical prostatectomy. Int J Radiat Oncol Bio Phys 23: 141–145
Schild SE, Wong WW, Grado GL, Halyard MY, Novicki DE, Swanson SK, Larson TR, Ferrigni RG (1996) The results of radical retropubic prostatectomy and adjuvant therapy for pathological stage C prostate cancer. Int J Radiat Oncol Biol Phys 34: 535–541
Syndicus I, Pickles T, Kostashuk E, Sullivan LD (1996) Postoperative radiotherapy for stage pT3 carcinoma of the prostate: improved local control. J Urol 155: 1983–1986
van den Ouden D, Bentvelsen FM, Boeve ER, Schröder FH (1993) Positive margins after radical prostatectomy: correlation with local recurrence and distant progression. Br J Urol 72: 489–494
Wiegel T, Bressel M, Arps H, Hübener KH (1992) Radiotherapy of local recurrence following radical prostatectomy. Strahlenther Onkol 168: 333–336
Wiegel T, Schmidt R, Kriill A, Schwarz R, Sommer K, Hübener KH (1993) Advantage of three-dimensional treatment planning for localized radiotherapy of early stage prostate cancer. Strahlenther Onkol 168: 692–697
Wiegel T, Bressel M (1994) Influence of the extent of nodal involvement on the outcome in stage D1 prostate cancer. Radiat Oncol Invest 2: 144–151
Wiegel T, Bressel M (1995) Adjuvant radiotherapy following radical prostatectomy —results of 56 patients. Eur J Cancer 31 A: 5–11
Wiegel T, Steiner U, Hinkelbein W (1997) Strahlentherapie nach radikaler Prostatektomie. Indikationen, Ergebnisse und Nebenwirkungen. Strahlenther Onkol 173: 309–315
Wu JJ, King SC, Montana GS, McKinstry CA, Anscher MS (1995) The efficacy of postprostatectomy radiotherapy in patients with an isolated elevation of serum prostate-specific antigen. Int J Radiat Oncol Biol Phys 32: 317–323
Zagars GK, Pollack A, Kavadi VS, von Eschenbach AC (1995) Prostate-specific antigen and radiation therapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 32: 293–306
Zietman AL, Shipley WU (1993) Randomized trials in loco regionlly confined prostate cancer: past, present and future. Semin Radiat Oncol 3: 210–220
Zietman AL, Edelstein RA, Coen JJ, Babayan RK, Krane RJ (1994) Radical prostatectomy for adenocarcinoma of the prostate: the influence of preoperative and pathologic findings on biochemical disease-free outcome. Urology 43: 828–833
Zietman AL, Coen JJ, Dallow KC, Shipley WU (1995) The treatment of prostate cancer by conventional radiation therapy: an analysis of long-term outcome. Int J Radiat Oncol Biol Phys 32: 287–292
Zimmermann F, Molls M (1996) Strahlentherapie des Prostatakarzinoms. Onkologe 2: 229–234
Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP, Barrett DM (1995) Long term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 152: 1850–1858
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wiegel, T. Welchen Stellenwert hat die Strahlentherapie in der Therapie des Prostatakarzinoms?. Der Urologe B 38, S58–S64 (1998). https://doi.org/10.1007/s001310050377
Published:
Issue Date:
DOI: https://doi.org/10.1007/s001310050377